TNFRSF10B and colorectal cancer: The DR5 antibody tigatuzumab has been studied in Phase II clinical trials for NSCLC (NCT00991796), pancreatic cancer (NCT00521404), ovarian cancer (NCT00945191), colorectal cancer (NCT01124630), and triple-negative breast cancer (TNBC) (NCT01307891) [118].